Actinium Pharmaceuticals, Inc. (ATNM) vs Metagenomi Therapeutics, Inc. (MGX)
- Actinium Pharmaceuticals, Inc. ATNM 1.13 +6.60%
- Metagenomi Therapeutics, Inc. MGX 0.78 −8.24%
Actinium Pharmaceuticals, Inc. and Metagenomi Therapeutics, Inc. are both Biotechnology companies. Actinium Pharmaceuticals, Inc. and Metagenomi Therapeutics, Inc. are of similar size ($33.3M and $31.9M). Metagenomi Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Actinium Pharmaceuticals, Inc. trades at 3.1×. Actinium Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 2,731.2% against −59.8%. Actinium Pharmaceuticals, Inc. has the higher net margin (32.2% vs −689.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Actinium Pharmaceuticals, Inc. leads on 11 and Metagenomi Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | ATNM | MGX | Biotechnology median |
|---|---|---|---|
| Gross margin | 98.71% | 100.00% | 65.16% |
| Operating margin | 27.20% | (741.58%) | 0.00% |
| Net margin | 32.18% | (689.20%) | 0.00% |
| Free cash flow margin | (66.16%) | (632.67%) | 0.00% |
| Return on equity | 45.86% | (60.61%) | (56.36%) |
| Return on assets | 21.92% | (41.91%) | (48.04%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack